Kailera Therapeutics (KLRA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$1.09
- Estimate
- -$0.76
- Surprise
- -43.4%
- Score today
- 5.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Kailera Therapeutics (KLRA) reported a wider loss than forecast — diluted EPS of -$1.09 against the -$0.76 estimate (a 43.4% shortfall).
Coverage in the report window
- Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate — benzinga, 2026-08-12
Where TrendMatrix's rating stands now
TrendMatrix currently rates KLRA Sell at 5.5/10; no pre/post engine snapshot brackets this report.
0 of the last 2 quarters beat the estimate; this quarter's -43.4% surprise compares with a -304.3% four-quarter average. Next scheduled report: 2026-10-29.
What argues against it
- Quality below floor (2.5 < 4.0)
- Momentum score 3.3/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $17.17
- Price target
- $36.89
- Stop
- $15.97
- Upside to target
- +114.9%
- Reward-to-risk
- 9.7:1
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
KLRA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.23B
- P/E (fwd)
- -4.0
- 52-week range
- $16.39–$28.23
- Off 52-week high
- 39.2%
- RSI (14)
- 49
- Volume vs avg
- 0.82×
- Score today
- 5.5/10